Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer.

Full Abstract

BACKGROUND:
Although venlafaxine reduces self-reported hot flashes, no data have established the drug's impact on physiologically documented hot flashes. Two randomized, double-blind, placebo-controlled crossover trials examined the efficacy of two doses of venlafaxine in relation to physiological and self-reported hot flashes and other outcomes, including negative affect, fatigue, sleep, and quality of life.

METHODS:
Sample:
57 breast cancer survivors in the low-dose study; 20 in the high-dose study. Setting:
university cancer clinics in the Southeast and Midwest. Intervention:
37.5 mg of venlafaxine (low-dose study) or 75 mg of venlafaxine (high-dose study). Measures:
hot flash frequency (physiological monitor, diary, and event marker), hot flash severity (diary), hot flash bother (diary), and questionnaires for hot flash impact on daily life, negative affect, fatigue, sleep, and quality of life.

RESULTS:
Subjective but not physiological hot flash measures showed placebo effects. Venlafaxine resulted in modest decreases in hot flashes, but only hot flash interference improved differentially at the higher dose. The timing of venlafaxine's effects on hot flashes varied by dose. Only women with a > or =50% decrease in physiological hot flashes experienced significant improvement in fatigue, sleep quality, and quality of life. Although side effects were mild, most patients discontinued venlafaxine long-term.

CONCLUSIONS:
Although venlafaxine resulted in modest and acute reductions in hot flashes with few side effects, it may not be tolerable to some patients long-term. At least 50% relief in physiological hot flashes may be needed for patients to demonstrate improvement in other outcomes, including decreased fatigue, improved sleep, and improved quality of life.

Learn Faster Today Improve your study skills

Author information

Author/s: Carpenter, Janet S (JS); Storniolo, Anna Maria (AM); Johns, Shelley (S); Monahan, Patrick O (PO); Azzouz, Faouzi (F); Elam, Julie L (JL); Johnson, Cynthia S (CS); Shelton, Richard C (RC);

Affiliation: Indiana University, 1111 Middle Drive NU340D, Indianapolis, Indiana 46202, USA. carpentj(-atsign-)iupui.edu

Grants: NR01 NR05261 (Agency:NINR NIH HHS)

Journal and publication information

Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural

Journal: The oncologist (Oncologist), published in United States. (Language: eng)

Reference: 2007-Jan; vol 12 (issue 1) : pp 124-35

Dates: Created 2007/01/17; Completed 2007/03/16; Revised 2007/12/03;

PMID: 17227907, status: MEDLINE (last retrieval date: 12/26/2008)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article (including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Adult
Breast Neoplasms - complications
Cyclohexanols - therapeutic use
Disease-Free Survival
Double-Blind Method
Female

Female
Hot Flashes - drug therapy; etiology
Humans
Placebos
Serotonin Uptake Inhibitors - therapeutic use
Treatment Outcome

Associated Chemicals: Cyclohexanols (0) ; Placebos (0) ; Serotonin Uptake Inhibitors (0) ; venlafaxine (93413-69-5)

These are the highest related articles currently in the database:

See 100+ related articles.